olfactory receptor family 4 subfamily A member 19 pseudogeneGenealiases: []
Q-omics provides the consensus-scored OR4A19P profile across patient tissues and cancer cell-line models. OR4A19P expression is associated with patient survival in 10 of 34 cancer types, with the highest sampling consensus in THYM. Among the 18 cancer types available for tumor–normal comparison, OR4A19P is differentially expressed in 1, with the highest sampling consensus in BRCA. Additionally, OR4A19P RNA expression shows 6,131 significant gene co-expression associations, with the highest sampling consensus in LUSC. Together, these results highlight THYM, BRCA, and LUSC as cancer lineages where OR4A19P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for OR4A19P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes OR4A19P survival associations across molecular data types. OR4A19P RNA expression shows survival associations in the most cancer types (10). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible OR4A19P RNA expression–survival associations across cancer types. High OR4A19P expression shows unfavorable associations in THYM, UCEC, SARC and LAML, but favorable associations in ESCA and BRCA. The THYM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify THYM as the clearest survival context for OR4A19P RNA expression.
This table summarizes OR4A19P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for OR4A19P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. OR4A19P shows higher tumor expression in BRCA. The BRCA box plot shows higher OR4A19P RNA expression in tumor versus normal tissue (log2 FC = +0.029, t-test p = .003).
This table shows molecular features associated with OR4A19P in patient tissues and cancer cell lines. In patient samples, OR4A19P shows the broadest associations at the RNA and protein expression levels, with LUSC recurring as the lineage with the largest associated feature set.
